ClinicalTrials.Veeva

Menu
M

MI Skin Innovations, LLC. | Northville, MI

Research site

Site insights

Top conditions

Top treatments

EVO756
PF-07264660
Tirzepatide
Ixekizumab
PF-07275315

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Syed Rahman

Verified by this site

Active trials

4 of 4 total trials

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa (COMPASS 2-HS)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Enrolling
Hidradenitis Suppurativa (HS)
Other: Placebo for BFB759
Biological: BFB759

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07275315
Other: Placebo

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Active, not recruiting
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Enrolling
Chronic Spontaneous Urticaria
Drug: EVO756
Drug: Placebo control

Trial sponsors

E
Lilly logo
Pfizer logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems